Vanda to release phase 2 data for sleep disorder compound at professional society meeting

By Lisa Kerner

Charlotte, N.C., June 13 - Vanda Pharmaceuticals Inc. said it will present phase 2 data for its sleep disorder compound VEC-162 at the SLEEP 2006 20th Anniversary Meeting of the Associated Professional Sleep Societies in Salt Lake City.

Shantha M.W. Rajaratnam, division of sleep medicine, Brigham and Women's Hospital, Harvard Medical School, will present "The Melatonin Agonist VEC-162 Immediately Phase-Advances the Human Circadian System," according to a company news release.

Located in Rockville, Md., Vanda is a biopharmaceutical company focused on the development and commercialization of clinical-stage product candidates for central nervous system disorders.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.